Fragile X syndrome is an X-linked trinucleotide repeat expansion disorder in the FMR1 gene, representing the most common inherited cause of intellectual disability and autism spectrum features in children, particularly boys, typically presenting in early childhood with developmental delay, characteristic facial features, and behavioral difficulties.

Exam domain	One-glance essentials
Definition / diagnosis	X-linked neurodevelopmental disorder caused by FMR1 full-mutation expansion ^[1] Full mutation usually means over 200 CGG repeats with methylation ^[1]
Epidemiology / risks	Premutation alleles can expand during maternal transmission ^[1] Anticipation and sex modify expression ^[1]
Core mechanism	Methylation silences FMR1 and reduces FMRP, impairing synaptic regulation ^[1] Males are generally more severely affected ^[1]
Clinical picture	Intellectual disability, autism traits, long face and large ears ^[1] Macro-orchidism appears after puberty; hyperactivity and anxiety are common ^[1]
Investigations	PCR plus methylation-sensitive testing sizes the CGG repeat ^[2] Assess development, autism, hearing, vision and cardiac findings ^[2]
Management	Early speech, occupational, behavioural and educational intervention ^[3] Treat ADHD, anxiety, seizures and sleep problems symptomatically ^[3]
Complications	Seizures, behavioural dysregulation and family stress ^[4] Premutation carriers risk tremor/ataxia and primary ovarian insufficiency ^[4]
Prevention / follow-up	Cascade-test relatives with genetic counselling ^[3] Explain reproductive options and premutation-associated disease ^[3]
Exam traps	*A standard chromosomal microarray may miss repeat expansion* ^[2] Premutation carriers are not simply unaffected carriers ^[3]

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 496–497)

^[2] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497)

^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497)

^[4] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497)

Fragile X Syndrome (FXS) in Paediatrics

Fragile X syndrome (FXS) is an X-linked genetic disorder caused by a trinucleotide (CGG) repeat expansion in the FMR1 (Fragile X Mental Retardation 1) gene located at chromosome Xq27.3, leading to decreased or absent production of Fragile X Messenger Ribonucleoprotein (FMRP) ^[1]^[2]^[3].

Breaking down the name:

"Fragile X" → refers to the classical cytogenetic finding of a "fragile site" on the long arm of the X chromosome (Xq27.3), where the chromatin fails to condense properly, making it appear as though the chromosome is "breaking" or "fragile" at that point under specific culture conditions
"Syndrome" → a constellation of features (intellectual disability, characteristic facial features, behavioural phenotype, connective tissue findings) that occur together

It is the most common inherited cause of intellectual disability and a significant single-gene cause of autism spectrum disorder (ASD) ^[2].

High Yield – GC Lecture Point

FXS is classified as a single-gene, X-linked disorder – an example of "simple causality" in the aetiology of psychiatric and developmental disorders, as explicitly highlighted in CFB (PSY04) ^[4]. This contrasts with most psychiatric disorders, which are multifactorial.

2. Epidemiology

Parameter	Value
Full mutation prevalence in males	1 in 4,000 – 1 in 7,000 ^[2]
Full mutation prevalence in females	Approximately 1/2 to 2/3 of male prevalence (roughly 1 in 6,000 – 1 in 11,000) ^[2]
Premutation carrier rate in males	1 in 750 – 850 ^[2]
Premutation carrier rate in females	1 in 250 – 300 ^[2]
Male-to-female clinical expression ratio	~2:1 (males more severely affected) ^[1]

Why males are more severely affected than females: Males have only one X chromosome (XY). If their single FMR1 gene carries the full mutation, they have zero functional copies → absent FMRP → fully affected. Females (XX) have two X chromosomes; even with a full mutation on one X, the other X may still produce some FMRP (depending on X-inactivation patterns). This is why 40–50% of female carriers can have learning difficulties, usually mild-to-moderate ^[1].
FXS is the most common inherited cause of intellectual disability – it is important to distinguish "inherited" from "most common genetic cause" (which is Down syndrome, usually arising de novo from meiotic non-disjunction rather than being inherited).
FXS accounts for approximately 2–3% of all intellectual disability and is present in ~5% of males with ID of unknown cause referred for genetic evaluation.
~10% of children with ASD have an identifiable genetic disorder, of which Fragile X syndrome is one of the most common ^[5]^[6].

Exam Pearl

When asked "What is the most common inherited cause of intellectual disability?" → Fragile X syndrome. When asked "What is the most common genetic cause of intellectual disability?" → Down syndrome (Trisomy 21). The distinction matters.

3. Anatomy and Function of FMR1/FMRP

Location: Xq27.3 (long arm of X chromosome, band 27.3) ^[1]^[2]
Normal function: Encodes FMRP (Fragile X Messenger Ribonucleoprotein) – previously called "Fragile X Mental Retardation Protein"
The 5' untranslated region (5' UTR) of the FMR1 gene contains a CGG trinucleotide repeat tract
Normal individuals have approximately 5–44 CGG repeats ^[1]^[2]

FMRP is an RNA-binding protein that is highly expressed in the brain (especially in neurons of the hippocampus, cortex, and cerebellum) and in the testes. Its functions include:

Synaptic plasticity regulation: FMRP acts as a translational repressor – it binds to mRNA at synapses and controls which proteins are made locally at the synapse. This is critical for activity-dependent synaptic remodelling (the process by which synapses strengthen or weaken in response to neuronal activity – the basis of learning and memory).
Dendritic spine maturation: FMRP regulates dendritic spine morphology. Without FMRP, dendritic spines are immature, long, thin, and tortuous (resembling immature/fetal spines) rather than the normal short, mushroom-shaped mature spines → this leads to aberrant synaptic connectivity → impaired learning and cognitive function.
mGluR5 signalling pathway: FMRP normally acts as a "brake" on metabotropic glutamate receptor 5 (mGluR5)-mediated protein synthesis at the synapse. Without FMRP, there is excessive mGluR5-driven signalling → excessive long-term depression (LTD) → synaptic dysfunction. This is the basis of the "mGluR theory of Fragile X", which has driven therapeutic research.
Other tissues: FMRP is also expressed in testes (relevant to macro-orchidism) and connective tissues (relevant to joint laxity, mitral valve prolapse).

Why Does Absent FMRP Cause Intellectual Disability?

Think of FMRP as the "quality control officer" at the synapse. It ensures that only the right proteins are synthesised at the right time in response to neuronal activity. Without this quality control, there is unregulated, excessive protein synthesis at the synapse → abnormal synapse formation and plasticity → the brain cannot properly encode, store, or retrieve learned information → intellectual disability.

4. Aetiology and Pathophysiology

GC Lecture High Yield

Trinucleotide repeat expansion is an unusual genetic mechanism where an unstable expansion of a trinucleotide repeat sequence (TRS) causes disease. The severity depends on whether the repeat is in a coding vs. non-coding region of the gene ^[1]^[3]:

In coding sequence: produces a protein with excess amino acids (e.g., polyglutamine) → toxic protein → neurodegeneration (e.g., Huntington disease, spinocerebellar ataxia)
In non-coding sequence: ↓ protein production (e.g., Fragile X syndrome, Friedreich ataxia)
Severity ↑ upon generations because triplet repeats expand between subsequent generations → this is called anticipation ^[1]^[3]

FXS is caused by expansion of CGG repeats in the 5' untranslated region (non-coding) of the FMR1 gene → this is in the non-coding region, so the mechanism is ↓/absent FMRP production (not toxic protein) ^[1]^[2].

Category	CGG Repeat Number	Molecular Consequence	Clinical Significance
Normal	~5–44	Normal FMRP production	Unaffected
Intermediate (Grey zone)	45–54	Stable or mildly unstable	Usually unaffected; may expand in offspring
Premutation	~55–200	FMR1 gene remains transcriptionally active; FMRP is produced	Classic FXS phenotype does NOT occur; but associated with a spectrum of clinical findings (FXTAS, FXPOI) ^[2]
Full mutation	> 200	Hypermethylation of FMR1 → transcriptional silencing → absent FMRP	Classic FXS phenotype ^[1]^[2]

CGG repeats expand beyond ~200
       ↓
5' UTR region becomes abnormally long
       ↓
Triggers HYPERMETHYLATION of CpG islands in the FMR1 promoter region
       ↓
DNA methylation = epigenetic silencing (methyl groups physically block
transcription factors from binding → gene is "turned off")
       ↓
FMR1 gene is SILENCED → no mRNA transcribed
       ↓
No FMRP produced
       ↓
Loss of translational regulation at synapses
       ↓
Excessive unregulated protein synthesis → abnormal dendritic spines
→ impaired synaptic plasticity → intellectual disability
+ Effects on connective tissue, testes, cardiac valves

Almost all (99%) cases of FXS are caused by trinucleotide repeat expansion; rare causes include point mutations, deletions, or missense mutations in FMR1 ^[1]^[2].

This is a crucial concept. Premutation carriers (55–200 repeats) do NOT have absent FMRP. Instead, their FMR1 gene is transcriptionally active – in fact, it is overactive. The expanded CGG repeat leads to elevated FMR1 mRNA levels (2–8 times normal). This excess mRNA itself is toxic (RNA gain-of-function toxicity), leading to distinct premutation-associated conditions:

Premutation Condition	Who Is Affected	Pathophysiology
Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) ^[1]	Males > 50 years (occasionally females)	Toxic mRNA forms nuclear inclusions in neurons and astrocytes → progressive cerebellar ataxia, intention tremor, cognitive decline, parkinsonism
Fragile X-associated Primary Ovarian Insufficiency (FXPOI)	Female premutation carriers	Toxic mRNA damages ovarian follicles → premature menopause (before age 40) in ~20% of female premutation carriers
Neurodevelopmental issues	Children with premutation	Some may have ADHD, anxiety, or mild learning difficulties (though most are cognitively normal)

Full Mutation vs. Premutation – Different Mechanisms!

A common exam mistake is conflating premutation and full mutation. They have fundamentally different molecular mechanisms:

Full mutation ( > 200 repeats): Gene is silenced → absent protein (loss of function)
Premutation (55–200 repeats): Gene is overactive → excess mRNA (RNA toxicity/gain of function) The clinical phenotypes are therefore completely different.

FXS is classified as X-linked ^[1]^[4], but its inheritance pattern is unusual due to the dynamic nature of trinucleotide repeat expansion.

Key inheritance principles:

CGG repeats are unstable during meiosis (especially during oogenesis/maternal transmission). They tend to expand when passed from parent to child.
The larger the premutation, the more likely it is to expand to a full mutation in the next generation. A mother with a premutation of 90 repeats has a much higher risk (~80%) of her child having a full mutation than a mother with 60 repeats (~5%).
Hence a male can be unaffected (normal transmitting male with premutation), then transmit to his daughter (who becomes a premutation carrier), and the grandson may be affected with the full mutation ^[1]. This is the Sherman Paradox – the observation that the risk of being affected increases in later generations.
Paternal transmission: When a premutation father passes his X chromosome to a daughter, the CGG repeat tends NOT to expand to a full mutation (repeats are relatively stable during spermatogenesis). So daughters of premutation males are virtually always premutation carriers, not fully affected.
Maternal transmission: When a premutation mother passes her X chromosome, the CGG repeat CAN expand to a full mutation → affected child. The risk depends on the size of the mother's premutation.

GC Lecture Slide – Sample Genetic Report

The GC 151 lecture slide ^[3] shows a clinical genetics letter for a boy named Lee Yan (DOB 10-1-1999) diagnosed with Fragile X syndrome:

Chromosomal studies showed normal karyotype (46,XY) – this is important! Standard karyotyping does NOT detect FXS. The fragile site is only seen under special culture conditions and molecular testing is the gold standard.
300 CGG repeats were found in the FMR1 gene (full mutation, confirming FXS)
65 CGG repeats found in his mother (premutation range – she is a carrier)
Maternal family members should be seen for genetic counselling – because other maternal relatives may carry the premutation/full mutation. This slide illustrates that FXS requires molecular analysis of CGG repeats, not standard karyotyping ^[3].

In every female cell, one of the two X chromosomes is randomly inactivated (lyonisation). In a female with the full mutation:

If the normal X is preferentially active in most cells → she produces adequate FMRP → may be minimally or unaffected
If the mutant X is preferentially active in most cells → she produces little FMRP → more significantly affected

This explains the wide variation in degree of impairment in females with full mutation ^[2]. The "activation ratio" (proportion of cells with the normal X active) correlates with cognitive outcome.

5. Classification

Classification	CGG Repeats	Key Features
Normal	5–44	No clinical significance
Intermediate	45–54	May be unstable; genetic counselling may be offered
Premutation	55–200	Risk of FXTAS (males), FXPOI (females), risk of expansion to full mutation in offspring
Full mutation	> 200	Classic FXS phenotype

Mosaicism can occur (some cells have methylated full mutation, others have unmethylated premutation or even normal alleles) → these individuals may have milder phenotypes
IQ range in affected males: 20–80, mean ~50 (moderate to severe ID) ^[1]

Condition	Population	Mechanism
Fragile X Syndrome (FXS)	Children (both sexes, males > females)	Full mutation → absent FMRP
FXTAS	Older adults (males > 50y) with premutation	RNA toxicity from excess FMR1 mRNA
FXPOI	Adult females with premutation	RNA toxicity → ovarian damage

6. Clinical Features

The clinical features of FXS are age-dependent. In early childhood, the phenotype may be subtle – intellectual disability or developmental delay is often the presenting feature. The classical physical features become more apparent with age, especially after puberty.

Symptom	Pathophysiological Basis	Age of Presentation
Developmental delay / Intellectual disability	Absent FMRP → impaired synaptic plasticity and dendritic spine maturation → deficient learning and memory circuits	Infancy onwards (may be the first concern)
Speech and language delay	Disproportionately affected; FMRP is crucial for language network development; often cluttered, repetitive speech ("litany-like")	Toddler years
Learning difficulties (especially maths, executive function)	FMRP required for frontal lobe-dependent executive function and working memory	School age
Autistic features / ASD	~30% of males with FXS meet DSM-5 criteria for ASD; FMRP regulates synaptic proteins implicated in ASD pathways (e.g., SHANK3, neuroligins) ^[5]^[6]	Early childhood
ADHD symptoms (inattention, hyperactivity, impulsivity)	Dysregulated catecholamine signalling due to absent FMRP modulation of dopaminergic/noradrenergic circuits	Preschool – school age
Anxiety (social anxiety, selective mutism, generalised anxiety)	Amygdala hyperreactivity – FMRP normally dampens amygdala responses to social/sensory stimuli; without it, there is exaggerated fear response	Childhood, may worsen in adolescence
Sensory hypersensitivity (tactile defensiveness, hyperacusis)	Aberrant sensory processing due to unregulated synaptic excitability (excessive mGluR5 signalling)	Early childhood
Gaze aversion	Social anxiety + sensory overload from eye contact (distinct from ASD gaze aversion – in FXS, children are socially interested but avoidant)	Early childhood
Hand flapping, hand biting	Stereotypic behaviours; overlap with ASD; likely related to sensory self-stimulation	Toddler – childhood
Sleep disturbances	Dysregulated melatonin production; FMRP involved in circadian rhythm gene regulation	Infancy onwards
Seizures (~10–20% of males with FXS)	FMRP regulates GABA and glutamate receptor expression; its absence creates an excitation-inhibition imbalance favouring excitability	Childhood; often benign, may remit by adolescence ^[7]

6B. Signs (What the clinician observes on examination)

Sign	Pathophysiological Basis	Notes
Macrocephaly	FMRP involved in regulating brain growth; its absence leads to accelerated brain growth in early childhood	Head circumference often > 97th centile; brain MRI may show increased caudate volume
Long face with broad forehead	Connective tissue dysplasia due to absent FMRP (FMRP regulates extracellular matrix protein expression)	Becomes more prominent with age
Large, everted (prominent) ears	Same connective tissue mechanism; ears appear "cupped" or "bat-like"	One of the most recognisable features; present from infancy
Prominent mandible (prognathism)	Connective tissue laxity + possibly altered growth factor regulation in craniofacial development	More evident after puberty
High-arched palate	Connective tissue dysplasia	May contribute to feeding difficulties in infancy

Sign	Pathophysiological Basis	Notes
Joint laxity (hyperextensibility)	FMRP regulates elastin and collagen-related gene expression; absent FMRP → connective tissue weakness	Especially finger joints; may resemble Ehlers-Danlos phenotype
Flat feet (pes planus)	Ligamentous laxity of the foot arches	Common
Scoliosis	Connective tissue laxity + hypotonia → vertebral malalignment	May require monitoring
Soft, velvet-like skin	Connective tissue dysplasia

Sign	Pathophysiological Basis	Notes
Macro-orchidism	FMRP normally regulates Sertoli cell proliferation and seminiferous tubule development; its absence leads to excessive Sertoli cell proliferation → testicular enlargement. Not due to increased testosterone.	Develops after puberty (testicular volume > 30 mL, normal adult is 15–25 mL); present in > 80% of post-pubertal males ^[1]

Sign	Pathophysiological Basis	Notes
Mitral valve prolapse (MVP)	Connective tissue dysplasia → myxomatous degeneration of mitral valve leaflets (similar mechanism to Marfan syndrome)	Present in ~50% of adults with FXS; usually mild; may cause mid-systolic click on auscultation ^[1]
Aortic root dilatation	Connective tissue abnormality (less common)	Rare

Sign	Pathophysiological Basis	Notes
Intellectual disability: moderate-severe in males (IQ 20–80, mean ~50)	See above – synaptic dysfunction	Females typically milder (IQ may be normal or borderline) ^[1]
Hypotonia (in infancy)	CNS + connective tissue involvement	May present as "floppy infant"
Motor clumsiness / coordination difficulties	Cerebellar involvement (FMRP expressed in Purkinje cells)
Perseverative speech	Executive function impairment (frontal lobe dysfunction)	Repeating phrases, echolalia
Fragile X-associated tremor/ataxia syndrome (FXTAS)	RNA toxicity from premutation – NOT from full mutation	Occurs in older adults with premutation, not children with FXS ^[1]

Age Group	Key Features
Neonate/infant	May be normal at birth; subtle hypotonia, large head, feeding difficulties, prominent ears may be noted. Often NOT diagnosed at this stage unless there is a family history.
Toddler (1–3 years)	Developmental delay becomes evident (especially speech/language); hand flapping; may be referred for ASD evaluation
Preschool (3–5 years)	ADHD symptoms emerge; anxiety; learning difficulties become more apparent
School age (6–12 years)	ID becomes clearly defined; seizures may occur; behavioural challenges; facial features become more recognisable
Adolescence/post-puberty	Macro-orchidism develops; facial features most prominent (long face, prominent jaw); MVP may be detected; seizures often remit

~40–50% of females with the full mutation have some degree of learning difficulty, but this is typically mild to moderate ^[1]. The variability depends on X-inactivation patterns:

~25% have normal IQ but may still have executive function difficulties, anxiety, or social difficulties
~25% have borderline IQ (70–84)
~25% have mild ID
Physical features are usually milder or absent

Domain	Features	Mechanism
Craniofacial	Macrocephaly, long face, broad forehead, large everted ears, prominent mandible	Connective tissue dysplasia + abnormal brain growth
Neurological	Moderate-severe ID (males), learning difficulties, ASD, ADHD	Absent FMRP → synaptic dysfunction
Behavioural	Anxiety, gaze aversion, hand flapping, sensory hypersensitivity	Amygdala hyperreactivity + sensory processing dysfunction
Musculoskeletal	Joint laxity, scoliosis, flat feet	Connective tissue dysplasia
Genital	Macro-orchidism (post-pubertal)	Sertoli cell proliferation
Cardiovascular	MVP	Myxomatous valve degeneration
Seizures	~10–20%, often remit by adolescence	Excitation-inhibition imbalance

7. Family-Centred Care and Communication Considerations

FXS is often diagnosed after a period of diagnostic uncertainty ("diagnostic odyssey") – parents may have noticed developmental delay but not received answers. Be empathetic about this journey.
Explain the X-linked inheritance clearly using diagrams – mothers who are carriers often feel guilt. Emphasise that this is not anyone's "fault."
Genetic counselling for the maternal family is essential ^[3] – maternal aunts, grandmothers, and cousins may carry the premutation/full mutation and may be at risk for FXTAS, FXPOI, or having affected children.
Prenatal and preimplantation genetic testing is available for future pregnancies.

For genetic testing in children, parental consent is obtained. In adolescents, assent should be sought where cognitively appropriate.
Cascade genetic testing of other family members should be offered with genetic counselling support.

High Yield Summary

Fragile X Syndrome – Key Points for Exams:

Most common inherited cause of intellectual disability (distinguish from Down syndrome, which is the most common genetic cause overall)
X-linked; FMR1 gene at Xq27.3; CGG trinucleotide repeat expansion in the 5' UTR (non-coding region)
99% caused by trinucleotide repeat expansion → hypermethylation → absent FMRP
Repeat ranges: Normal (~5–44), Premutation (55–200), Full mutation ( > 200)
Full mutation: gene silenced → no FMRP → loss of function
Premutation: gene overactive → excess mRNA → RNA toxicity (FXTAS, FXPOI)
Anticipation: repeats expand through generations (especially maternal transmission)
Sherman Paradox: unaffected male → carrier daughter → affected grandson
Clinical triad: Intellectual disability + Large ears/long face + Macro-orchidism (after puberty)
Associated features: ASD (~30%), ADHD, anxiety, joint laxity, MVP, seizures (10–20%)
Females: 40–50% with full mutation have learning difficulty (variable due to X-inactivation)
Diagnosis: Molecular analysis of CGG repeat number in FMR1 (NOT standard karyotype)
Standard karyotype is NORMAL (46,XY) – fragile site only seen under special conditions
Genetic counselling of maternal relatives is mandatory

Active Recall - Fragile X Syndrome

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 496–497) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880–881) ^[3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) ^[4] GC Lecture slides: CFB (PSY04) Aetiology of Psychiatric Disorders.pdf (p. 8) ^[5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) – ASD aetiology section ^[6] Senior notes: Ryan Ho Psychiatry.pdf (p. 256) – ASD aetiology section ^[7] Senior notes: Ryan Ho Neurology.pdf (p. 102) – Genetic aetiology of epilepsy

Differential Diagnosis of Fragile X Syndrome

A child presenting with features suggestive of FXS — developmental delay, intellectual disability (ID), behavioural concerns (ASD/ADHD features), and/or characteristic dysmorphic features — sits within a broad differential. The key clinical challenge is that many of these features are non-specific in early childhood. A toddler with speech delay and hypotonia could have dozens of possible diagnoses. The classic FXS triad (ID + long face with large ears + macro-orchidism) is often only fully apparent after puberty — so in the younger child, you must differentiate FXS from other causes of global developmental delay (GDD), intellectual disability, and syndromic/dysmorphic presentations.

The differential diagnosis can be organised along several clinical axes:

Child presenting with GDD / intellectual disability (the most common presentation of FXS)
Child presenting with ASD / behavioural phenotype
Child presenting with specific dysmorphic features (long face, large ears, macro-orchidism, joint laxity)
Child with connective tissue features (joint laxity, MVP, tall habitus)

The approach depends on the presenting feature. In practice, a child with FXS most often presents with:

Developmental delay or intellectual disability (most common referral reason)
Behavioural concerns (ASD, ADHD, anxiety)
Family history of intellectual disability or known FXS/premutation

Less commonly, the presentation is triggered by recognition of dysmorphic features or macro-orchidism (post-pubertal).

7B. Differential Diagnosis Table — Organised by Clinical Overlap

These are the conditions most likely to be confused with FXS in a paediatric genetics or developmental paediatrics clinic.

Condition	Genetic Basis	Overlapping Features with FXS	Distinguishing Features	Key Investigation
Down Syndrome (Trisomy 21)	Trisomy 21 (47,XX/XY,+21)	ID (usually mild-moderate), hypotonia, ASD in some, congenital heart disease	Flat face, upslanting palpebral fissures, epicanthic folds, single palmar crease, Brushfield spots, short stature, AVSD most common cardiac defect ^[8]	Karyotype / FISH / CMA
Sotos Syndrome ("cerebral gigantism")	NSD1 gene (5q35), AD	Macrocephaly, ID (usually mild), long face, behavioural difficulties (ADHD, anxiety), advanced bone age	Overgrowth (tall stature with macrocephaly from birth), prominent forehead, sparse frontotemporal hair, pointed chin, downslanting palpebral fissures	NSD1 gene testing
Williams Syndrome	7q11.23 microdeletion (elastin gene)	ID (mild), "cocktail party" personality (superficially sociable but impaired social cognition), joint laxity, cardiac involvement	Elfin facies (broad forehead, short nose, long philtrum, full lips), supravalvular aortic stenosis, peripheral PS, transient neonatal hypercalcaemia, renal artery stenosis, hypertension ^[9]	FISH / CMA for 7q11.23 deletion
Noonan Syndrome	RAS-MAPK pathway genes (PTPN11 most common), AD	Short stature, ID (mild in ~25%), cardiac involvement, joint laxity	Turner-like phenotype in both sexes: hypertelorism, ptosis, low-set ears, webbed neck, shield chest, right-sided cardiac lesions (pulmonary stenosis, HCM), cryptorchidism, bleeding tendency ^[8]^[9]	Gene panel (RASopathy genes)
Angelman Syndrome	Loss of maternal UBE3A (15q11-q13)	ID (severe), ASD features, seizures (~90%), happy demeanour	Severe ID with absent speech, ataxic gait ("puppet-like"), inappropriate laughter, microcephaly, seizure onset typically 1–3 years	Methylation analysis of 15q11-q13
Prader-Willi Syndrome	Loss of paternal 15q11-q13	Hypotonia (infancy), ID (mild-moderate), behavioural difficulties	Neonatal hypotonia with poor feeding → then hyperphagia and obesity (from ~2 years), short stature, hypogonadism, small hands and feet	Methylation analysis of 15q11-q13
Rett Syndrome	MECP2 mutation (Xq28), X-linked dominant	Predominantly females, ASD-like features, ID, seizures	Normal development until 6–18 months then regression, loss of purposeful hand movements (hand-wringing stereotypies), gait apraxia, deceleration of head growth	MECP2 gene testing
Klinefelter Syndrome (47,XXY)	47,XXY	ID (mild), tall stature, behavioural difficulties, small testes (cf. FXS: large testes)	Tall stature, eunuchoid habitus, small firm testes, gynecomastia, infertility (azoospermia), hypergonadotropic hypogonadism; usually presents in adolescence/adulthood ^[10]	Karyotype
Turner Syndrome	45,X (or variants)	Short stature, cardiac involvement, learning difficulties (non-verbal LD), webbed neck	Female only, short stature, shield chest, lymphoedema, coarctation of aorta, bicuspid aortic valve, streak gonads, primary amenorrhoea ^[10]	Karyotype

Exam Pearl – Sotos vs. FXS

Both Sotos syndrome and FXS cause macrocephaly + ID + long face. The key distinguisher is that Sotos has overgrowth (tall stature + advanced bone age), whereas FXS has normal to slightly tall stature with macro-orchidism after puberty. Sotos also has a pointed chin and sparse frontotemporal hair, features NOT seen in FXS.

Because FXS causes connective tissue features (joint laxity, MVP, flat feet, scoliosis), it can overlap with:

Condition	Genetic Basis	Overlapping Features with FXS	Distinguishing Features	Key Investigation
Marfan Syndrome	FBN1 gene (15q21.1), AD	Joint hypermobility, MVP, scoliosis, flat feet, long face	Tall stature with disproportionately long limbs (arm span > height), arachnodactyly, ectopia lentis (upward lens subluxation ~60%), aortic root dilatation/dissection, pectus deformity; NO intellectual disability ^[1]^[9]	Revised Ghent criteria; FBN1 gene testing
Ehlers-Danlos Syndrome (hypermobile type)	Various (COL5A1/A2 for classical; mostly unknown for hypermobile type)	Joint hypermobility, soft skin, MVP	Skin hyperextensibility, tissue fragility (easy bruising, poor wound healing), no ID, no characteristic facial features	Clinical (Beighton score); gene testing for classical type
Loeys-Dietz Syndrome	TGFBR1/TGFBR2, AD	MVP, joint laxity, scoliosis	Bifid uvula/cleft palate, hypertelorism, arterial tortuosity, aggressive aortic aneurysms; no ID	TGFBR gene testing

Key Differentiator: Marfan vs. FXS

Both can present with tall stature, joint laxity, MVP, flat feet, and scoliosis. However:

Marfan: NO intellectual disability; HAS ectopia lentis and aortic root dilatation
FXS: HAS intellectual disability and macro-orchidism; NO ectopia lentis The presence or absence of ID and lens subluxation is the clinical separator ^[1].

~30% of males with FXS meet criteria for ASD ^[5]^[6]. When a child presents primarily with autistic features, consider:

Condition	Genetic Basis	Overlapping Features	Distinguishing Features
Idiopathic ASD	Polygenic / multifactorial	ASD behaviours, speech delay, ADHD, sensory issues	No dysmorphic features, no ID (in ~50% of ASD), no macro-orchidism; diagnosed clinically by DSM-5 criteria
Tuberous Sclerosis Complex (TSC)	TSC1 (hamartin) / TSC2 (tuberin), AD	ASD (~40%), ID, seizures	Ash-leaf spots, facial angiofibromas, shagreen patch, cortical tubers on MRI, cardiac rhabdomyomas
Rett Syndrome	MECP2, X-linked dominant	ASD-like features, stereotypies, seizures	Regression after 6–18 months; hand-wringing; almost exclusively females
PTEN hamartoma syndrome	PTEN gene, AD	Macrocephaly, ASD, ID	Extreme macrocephaly (head circumference > 98th centile), hamartomas, increased cancer risk
22q11.2 Deletion Syndrome (DiGeorge)	22q11.2 microdeletion	ID (mild-borderline), behavioural difficulties, psychiatric features	Conotruncal cardiac defects (ToF, truncus arteriosus, interrupted aortic arch), thymic hypoplasia, hypocalcaemia, palatal anomalies ^[8]

High Yield – GC/Block C Lecture Point

Fragile X syndrome is listed alongside Down syndrome, muscular dystrophy, neurofibromatosis, and tuberous sclerosis as a genetic disorder associated with ASD (accounting for ~10% of ASD cases) ^[5]^[6]. When a child presents with ASD, it is important to consider these syndromic causes — particularly if there are dysmorphic features, family history of ID, or seizures — as they change genetic counselling, prognosis, and management.

~10–20% of males with FXS have seizures ^[1]^[7]. Other genetic conditions causing seizures + ID include:

Condition	Key Features Distinguishing from FXS
Angelman Syndrome	Severe ID with absent speech, ataxic gait, seizures (~90%), happy demeanour, microcephaly (cf. FXS: macrocephaly)
Dravet Syndrome (SCN1A)	Severe myoclonic epilepsy of infancy; fever-triggered seizures from ~6 months; progressive cognitive decline
Rett Syndrome	Regression, hand-wringing, almost exclusively female
Tuberous Sclerosis	Infantile spasms, cortical tubers, skin lesions

Category	Examples	Distinguishing from FXS
Perinatal insult	Hypoxic-ischaemic encephalopathy, prematurity-related brain injury	History of difficult delivery, NICU stay; brain MRI shows acquired injury
Metabolic disorders	Phenylketonuria (PKU), hypothyroidism, storage disorders	Newborn screening positive; specific biochemical markers; may have regression
Environmental	Fetal alcohol spectrum disorder (FASD), lead poisoning	Maternal alcohol history; smooth philtrum, thin upper lip, short palpebral fissures (FASD); blood lead levels
Chromosomal microarray abnormalities	Various copy number variants (CNVs)	Detected on CMA; variable phenotypes; no specific FXS features
Fanconi Anaemia	Short stature, radial ray anomalies, café-au-lait spots, pancytopenia ^[11]	Bone marrow failure; chromosome breakage study positive
Neurofibromatosis Type 1	Café-au-lait macules, neurofibromas, Lisch nodules, learning difficulties (but NOT usually moderate-severe ID) ^[12]	≥ 2/8 CAFESPOT criteria; NF1 gene testing

Clinical Question	Points Towards FXS	Points Away from FXS
Family history pattern?	X-linked: affected males on maternal side; females with mild LD; Sherman paradox	De novo (Down, many Marfan); AD pedigree (NF1, Marfan, Noonan); maternal inheritance only (mitochondrial)
Head size?	Macrocephaly	Microcephaly (Angelman, Rett); normal (most other conditions)
Facial features?	Long face, large everted ears, prominent mandible, broad forehead	Flat face + epicanthic folds (Down); elfin facies (Williams); pointed chin (Sotos)
Testicular size (post-pubertal)?	Macro-orchidism ( > 25 mL)	Small testes (Klinefelter, Prader-Willi); normal (most others)
Connective tissue signs?	Joint laxity, flat feet, MVP, scoliosis	Ectopia lentis + aortic root (Marfan); skin fragility (EDS)
Behavioural phenotype?	Social anxiety with gaze aversion (but socially interested), hand flapping, cluttered speech	Complete social disinterest (severe ASD); regression (Rett); hyperphagia (Prader-Willi)
Regression?	No regression (skills acquired slowly; apparent "decline" is slowing of acquisition relative to peers, not true loss) ^[2]	True regression → think Rett, metabolic/storage disorders, Dravet
Karyotype?	Normal (46,XY or 46,XX) ^[3]	Abnormal (Down: trisomy 21; Turner: 45,X; Klinefelter: 47,XXY)

Critical Point – FXS Does NOT Cause Regression

Cognitive level and adaptive behaviour skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills ^[2]. This is a subtle but important distinction. True regression (loss of previously acquired skills) should prompt investigation for Rett syndrome, metabolic/neurodegenerative disorders, or epileptic encephalopathy — not FXS.

Indications for molecular testing for FXS ^[2]:

In children:

Developmental delay
Borderline intellectual abilities or intellectual disabilities
Diagnosis of autism without a specific aetiology

In adults:

Females with primary ovarian insufficiency (POI)
Patients > 50 years old with progressive cerebellar ataxia and intention tremor (FXTAS)
Adults with typical physical features and intellectual disability without a specific aetiology

High Yield – Indications for FXS Testing

The lecture slides and senior notes emphasise that any child with unexplained GDD/ID or ASD should be considered for FXS molecular testing ^[2]^[3]. This is particularly true if there is a family history of intellectual disability, premature ovarian failure, or tremor/ataxia in maternal relatives. Standard karyotyping will NOT detect FXS — molecular analysis (CGG repeat sizing) is required ^[3].

High Yield for Exams — When asked "What is the differential diagnosis of Fragile X syndrome?", think of conditions that share the core features of FXS:

Rank	Condition	Why It Overlaps	Key Differentiator
1	Sotos Syndrome	Macrocephaly + long face + ID	Overgrowth, advanced bone age, pointed chin
2	Down Syndrome	Most common genetic cause of ID; hypotonia, ASD	Flat face, upslanting eyes, AVSD, trisomy 21 on karyotype
3	Idiopathic ASD	Behavioural overlap (30% of FXS meets ASD criteria)	No dysmorphism, no macro-orchidism, no connective tissue features
4	Marfan Syndrome	Joint laxity, MVP, tall habitus, long face	Ectopia lentis, aortic root dilatation, NO ID
5	Angelman Syndrome	Severe ID, seizures, happy demeanour	Absent speech, microcephaly (vs. macrocephaly in FXS), ataxic gait

Active Recall - Differential Diagnosis of Fragile X Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (pp. 458, 497) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) ^[3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) ^[5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) ^[6] Senior notes: Ryan Ho Psychiatry.pdf (pp. 251, 256) ^[7] Senior notes: Ryan Ho Neurology.pdf (p. 102) ^[8] Senior notes: Ryan Ho Cardiology.pdf (p. 185) ^[9] Senior notes: Maksim Paediatric Notes.pdf (p. 207) ^[10] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 507) ^[11] Senior notes: Block A - Pallor_ diagnosis of anaemia; nutritional anaemia; anaemia of systemic diseases.pdf (p. 42) ^[12] Senior notes: Ryan Ho Rheumatology.pdf (p. 172)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Fragile X Syndrome

Unlike many paediatric conditions (e.g., Kawasaki disease, rheumatic fever) that use clinical diagnostic criteria based on a combination of signs and symptoms, Fragile X syndrome is definitively diagnosed by molecular genetic testing. The clinical features — intellectual disability, characteristic facies, macro-orchidism, behavioural phenotype — are supportive and raise suspicion, but the diagnosis is confirmed (or excluded) by demonstrating the CGG repeat expansion in the FMR1 gene ^[1]^[2]^[3].

This is because:

The clinical phenotype is age-dependent and often subtle in young children — the very population in whom early diagnosis matters most for intervention.
Many features (developmental delay, hypotonia, large ears) are non-specific and shared by numerous other conditions (see DDx section).
Standard karyotyping (46,XY or 46,XX) is NORMAL in FXS ^[3] — the "fragile site" on the X chromosome is only visible under special folate-depleted culture conditions and is no longer used as a diagnostic method.

GC Lecture Slide – Critical Exam Point

The GC 151 lecture slide ^[3] explicitly demonstrates a clinical genetics report where:

Chromosomal studies showed normal karyotype (46,XY)
Diagnosis was made by molecular analysis: 300 CGG repeats in FMR1
Mother had 65 CGG repeats (premutation carrier)

This reinforces that karyotyping does NOT diagnose FXS — molecular testing for CGG repeat number is mandatory ^[3].

8B. Indications for Molecular Testing — Who Should Be Tested?

The most important clinical decision is recognising which children and adults warrant FXS molecular testing. Testing should be considered in the following situations ^[2]:

Clinical Scenario	Why Test?
Developmental delay (any domain)	FXS is the most common inherited cause of ID; early diagnosis enables early intervention ^[2]
Borderline intellectual abilities or intellectual disability of unknown aetiology	Must exclude FXS before labelling as "idiopathic"
Autism spectrum disorder without a specific identified aetiology	~2–6% of children with ASD have FXS; FXS is the most common single-gene cause of ASD ^[2]^[5]
Family history of intellectual disability (especially males on the maternal side)	X-linked pattern suggests FXS
Family history of premature ovarian insufficiency or tremor/ataxia in maternal relatives	Suggests premutation carrier status in the family
Characteristic physical features (macrocephaly, large ears, long face, joint laxity) ± ID	Clinical suspicion warrants confirmation

Clinical Scenario	Why Test?
Females with primary ovarian insufficiency (POI)	~20% of female premutation carriers develop FXPOI ^[2]
Patients > 50 years with progressive cerebellar ataxia and intention tremor	Consider FXTAS in premutation carriers ^[2]
Adults with typical physical features and ID without a specific aetiology	May have been undiagnosed in childhood

High Yield – When to Order FXS Testing

Any child with unexplained GDD, intellectual disability, or ASD should be considered for FXS molecular testing ^[2]. This is a standard part of the first-tier genetic workup for unexplained developmental delay in paediatric practice. Many guidelines now recommend FXS testing alongside chromosomal microarray (CMA) as the initial genetic investigations for unexplained GDD/ID.

The following algorithm outlines the clinical and laboratory pathway from suspicion to confirmed diagnosis and subsequent management steps.

8D. Investigation Modalities, Key Findings, and Interpretation

I. Primary Diagnostic Test: FMR1 Molecular Analysis

This is the gold standard and the only definitive diagnostic test for FXS ^[1]^[2]^[3].

Parameter	Detail
Method	Polymerase chain reaction (PCR) with primers flanking the CGG repeat region in the 5' UTR of FMR1
What it measures	Number of CGG repeats
Strength	Rapid, relatively inexpensive; accurately sizes alleles in the normal, intermediate, and premutation range
Limitation	Standard PCR cannot reliably amplify very large expansions ( > ~200 repeats) because the GC-rich repeat region forms stable secondary structures (hairpins) that block polymerase progression. A full mutation may therefore appear as a "blank" or absent allele on PCR
Interpretation of "absent allele" in a male	If a male shows no PCR product for FMR1, it suggests a very large expansion that PCR cannot amplify → must proceed to Southern blot
Triplet-primed PCR (TP-PCR)	A refinement that uses a primer within the repeat region, generating a characteristic "stutter" pattern on capillary electrophoresis. Can detect expansions into the premutation and full mutation range more reliably than standard PCR. Widely used as a screening tool

Parameter	Detail
Method	Genomic DNA is digested with restriction enzymes (e.g., EcoRI + EagI), separated by gel electrophoresis, transferred to membrane, hybridised with a labelled probe specific to the FMR1 region
What it measures	(1) Size of the CGG repeat expansion (including very large full mutations), and (2) Methylation status of the FMR1 promoter (EagI is a methylation-sensitive enzyme — it cuts unmethylated DNA but NOT methylated DNA)
Key findings	Normal male: single band at ~2.8 kb (EcoRI/EagI). Full mutation male: band shifts upward ( > 5.2 kb) due to expansion AND remains uncut by EagI (indicating methylation/gene silencing). Premutation: intermediate-sized band, cut by EagI (unmethylated, gene active)
Strength	Can size very large expansions; simultaneously determines methylation status (functionally important)
Limitation	Slower (takes days), requires more DNA, less widely available, more expensive than PCR

In practice, most laboratories use a two-step approach:

PCR (or TP-PCR) as the first-line screening test
Southern blot if PCR suggests a large expansion (absent allele) or to confirm full mutation and assess methylation

Interpreting the Molecular Report

When you receive a molecular report for FXS, look for three pieces of information:

CGG repeat number → determines the category (normal / intermediate / premutation / full mutation)
Methylation status → determines whether the gene is silenced (functionally relevant)
Mosaicism → some individuals have a mixture of premutation and full mutation cells (size mosaicism) or methylated and unmethylated full mutation cells (methylation mosaicism) → milder phenotype

CGG Repeats	PCR Result	Southern Blot	Methylation	Clinical Significance
5–44	Normal-sized band	Normal (~2.8 kb)	Unmethylated	Normal; no FXS
45–54	Slightly enlarged	Slightly enlarged	Unmethylated	Intermediate; may be unstable in future generations; genetic counselling
55–200	Enlarged band visible	Intermediate size	Unmethylated (gene active)	Premutation carrier; risk of FXTAS/FXPOI; risk of expansion to full mutation in offspring
> 200	Absent or smeared band ("blank allele" in males)	Large shifted band ( > 5.2 kb)	Methylated (gene silenced)	Full mutation = Fragile X syndrome confirmed
Mosaic	Variable	Mixed bands	Partially methylated	Size or methylation mosaicism; may have milder phenotype

It is essential to understand what standard genetic tests will and will not show in FXS.

Investigation	Expected Finding in FXS	Why It Doesn't Diagnose FXS
Standard karyotype	Normal (46,XY or 46,XX) ^[3]	The fragile site at Xq27.3 is only visible under special folate-depleted culture conditions (historical method, no longer used diagnostically). Standard G-banded karyotyping does not detect trinucleotide repeat expansions
Chromosomal microarray (CMA)	Normal (in 99% of FXS cases)	CMA detects copy number variants (deletions/duplications) but NOT trinucleotide repeat expansions. The rare 1% of FXS caused by FMR1 deletions may be detected by CMA, but the vast majority (99%) caused by CGG expansion will be missed
Whole exome/genome sequencing	May miss CGG repeat expansion	Standard short-read sequencing technologies have difficulty mapping repetitive regions. Newer long-read sequencing platforms can detect expansions, but this is not yet routine

Common Exam Trap

A normal karyotype does NOT exclude Fragile X syndrome ^[3]. This is a commonly tested point. If you are told "karyotype is 46,XY, normal" in a boy with intellectual disability, FXS is NOT excluded — you must specifically request FMR1 CGG repeat analysis to investigate FXS. Similarly, a normal CMA does not exclude FXS.

Once FXS is confirmed, additional investigations are performed to assess complications and guide multidisciplinary management:

Investigation	Purpose	Expected Findings in FXS	Age to Perform
Developmental assessment (e.g., Griffiths, Bayley scales)	Quantify cognitive, motor, language, adaptive function domains	Moderate-severe ID in males (IQ 20–80, mean ~50); mild-moderate in some females ^[1]	At diagnosis, then longitudinal
ASD-specific assessment (e.g., ADOS-2, ADI-R)	Screen for co-morbid ASD	~30% of males with FXS meet ASD criteria	At diagnosis if behavioural features present
ADHD assessment (e.g., Conners rating scales)	Screen for ADHD	Very common (~80% of males have ADHD features)	School age
Echocardiography	Screen for mitral valve prolapse (MVP)	MVP in ~50% of adults; less common in children	At diagnosis, repeat in adolescence/adulthood ^[1]
EEG	If seizures suspected	May show epileptiform discharges; seizures in ~10–20% of males ^[1]^[7]	Only if clinical seizures or concern
Ophthalmology assessment	Screen for strabismus, refractive errors	Strabismus common ^[2]	At diagnosis
Audiology	Screen for hearing difficulties	Recurrent otitis media may cause conductive hearing loss	At diagnosis
Orthopaedic assessment	Joint laxity, scoliosis, flat feet	Joint hypermobility, pes planus, scoliosis ^[1]	At diagnosis, then longitudinal
Testicular volume measurement	Document macro-orchidism	Testicular volume > 25 mL post-puberty (Prader orchidometer) ^[2]	Puberty and beyond

This is a mandatory part of the diagnostic pathway ^[3]. Once FXS is diagnosed in a child:

Mother → test for premutation/full mutation carrier status (determines recurrence risk for future pregnancies)
Maternal aunts, grandmother, female cousins → may carry premutation/full mutation; at risk for:
- Having affected children
- FXPOI (premature ovarian failure)
- FXTAS (in older males and occasionally females with premutation)
Siblings → test to determine if also affected (may have milder/undiagnosed phenotype)

The GC 151 lecture slide explicitly states: "We would see the other maternal family members and discuss the impact of the disease on them in our genetic counseling clinic" ^[3].

For families with known FXS/premutation status, reproductive options include:

Method	Timing	What It Tests	Notes
Chorionic villus sampling (CVS)	10–13 weeks gestation	CGG repeat number + methylation status from placental tissue	Earlier result than amniocentesis; small risk of miscarriage (~0.5–1%)
Amniocentesis	15–18 weeks gestation	CGG repeat number + methylation from amniotic fluid cells	Methylation status is more reliably interpreted than from CVS
Preimplantation genetic testing (PGT-M)	Before implantation (IVF required)	Tests embryos for CGG expansion prior to transfer	Avoids need for pregnancy termination decision; technically challenging due to repeat instability
Non-invasive prenatal testing (NIPT)	From ~10 weeks gestation	Cell-free fetal DNA in maternal blood	NOT routinely used for FXS (repeat expansions are difficult to detect in cfDNA); research use only

Counselling Point for Families

It is important to counsel premutation carrier mothers that the risk of CGG expansion to full mutation in offspring depends on the size of the maternal premutation. A mother with 60 CGG repeats has a ~5% risk of having a child with a full mutation, whereas a mother with 100+ repeats has > 90% risk. This information is crucial for reproductive decision-making.

Chromosome analysis showing a classical "fragile site" in the distal part of Xq (a visible gap or constriction at Xq27.3 due to local failure of chromatin condensation) was historically used to identify FXS ^[1]. This required culturing lymphocytes in folate-depleted or thymidine-stressed medium. However, this method is:

Insensitive (does not detect all carriers)
Non-specific (other fragile sites exist on the X chromosome)
Cannot distinguish premutation from full mutation
No longer used for clinical diagnosis — entirely replaced by molecular testing

Step	Action	Key Point
1	Clinical suspicion	Child with GDD/ID/ASD/characteristic features/family history
2	Order FMR1 CGG repeat analysis	Gold standard; NOT karyotype, NOT CMA ^[1]^[2]^[3]
3	PCR ± Southern blot	PCR for screening; Southern blot for sizing large expansions and methylation status
4	Interpret CGG repeat number	Normal ( < 45), intermediate (45–54), premutation (55–200), full mutation ( > 200)
5	Confirm methylation	Full mutation + methylation = gene silenced = FXS confirmed
6	Post-diagnosis workup	Developmental assessment, echo, ophthalmology, audiology, ASD/ADHD screening
7	Cascade family testing + genetic counselling	Mandatory — identify at-risk maternal relatives ^[3]
8	Reproductive counselling	CVS/amniocentesis/PGT-M options for future pregnancies

High Yield Summary – Diagnosis of FXS

FXS is diagnosed by molecular testing (FMR1 CGG repeat analysis), NOT by karyotype or CMA ^[3]
Karyotype is NORMAL in FXS (46,XY or 46,XX) ^[3]
Two-step molecular approach: PCR (screening) → Southern blot (confirmation of full mutation + methylation)
Full mutation = > 200 CGG repeats + hypermethylation → FMR1 silenced → absent FMRP
Premutation = 55–200 repeats → gene ACTIVE → RNA toxicity (not classic FXS but risk of FXTAS/FXPOI)
Test any child with unexplained GDD, ID, or ASD for FXS
Cascade testing of maternal relatives is mandatory after diagnosis
Post-diagnosis: developmental assessment, echo for MVP, ophthalmology, audiology, seizure monitoring

Active Recall - Diagnosis of Fragile X Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) ^[3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) ^[5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) ^[7] Senior notes: Ryan Ho Neurology.pdf (p. 102) ^[9] Senior notes: Maksim Paediatric Notes.pdf (p. 207)

Management of Fragile X Syndrome

There is no cure for Fragile X syndrome. There is no drug that restores FMRP production or reverses the methylation silencing of the FMR1 gene. Management is therefore supportive, symptomatic, and multidisciplinary, centred on:

Early diagnosis → early intervention (the single most impactful step) ^[2]
Optimising developmental potential through therapies and educational support
Managing co-morbid behavioural and medical conditions (ADHD, anxiety, ASD, seizures, cardiac, orthopaedic)
Family-centred care: genetic counselling, cascade testing, reproductive planning, psychosocial support
Surveillance for age-dependent complications (MVP, macro-orchidism, seizures)

GC / Senior Notes – Key Management Principle

"Important to make the diagnosis of FXS early so that appropriate interventions (speech and language therapy, special education support, genetic counselling) can be initiated" ^[2]. This is the core exam-relevant management statement — early identification enables early intervention, which improves long-term cognitive, behavioural, and adaptive outcomes.

9C. Non-Pharmacological Management (Cornerstone of Treatment)

Non-pharmacological interventions are the mainstay of FXS management. Medications play a supporting role for specific co-morbidities, but therapies and educational support are what most directly improve functional outcomes.

Therapy	Target	Rationale	Paediatric Considerations
Speech and Language Therapy (SLT) ^[2]	Expressive and receptive language, pragmatic communication, cluttered speech	Language delay is often the earliest and most significant developmental concern in FXS; FMRP is critical for language network development. SLT addresses articulation, vocabulary, narrative skills, and conversational pragmatics	Begin as soon as delay is identified (often by 18–24 months). Use visual supports, sign language augmentation, and structured language programmes. Address cluttered speech pattern (rapid, irregular rate) specifically
Occupational Therapy (OT)	Fine motor skills, sensory processing, self-care skills, handwriting	Sensory hypersensitivity (tactile defensiveness, hyperacusis) is a core feature due to excessive mGluR5 signalling; OT provides sensory integration therapy. Fine motor difficulties relate to hypotonia + joint laxity	Sensory diets (scheduled sensory input to modulate arousal), weighted vests, fidget tools. Adaptive equipment for feeding, dressing. Joint protection strategies for hypermobile joints
Physiotherapy (PT)	Gross motor development, hypotonia, balance, coordination	Hypotonia in infancy → delayed motor milestones. Joint laxity → instability. Cerebellar involvement → coordination difficulties	Core strengthening, balance training, gait assessment. Monitor for flat feet (orthotics may be needed). Scoliosis screening at each visit
Special Education / Individualised Education Programme (IEP) ^[2]	Academic learning, executive function, adaptive skills	IQ 20–80 (mean ~50) in males ^[1]; learning disabilities across all domains but particularly in quantitative/mathematical reasoning. Need structured, small-group or 1:1 instruction with visual learning strategies	Place in appropriate educational setting (mainstream with support vs. special school). Regular reassessment of cognitive level and adaptive skills. In Hong Kong: apply for special educational needs (SEN) support through Education Bureau
Behavioural Therapy	Challenging behaviours, anxiety, social skills	Anxiety (social anxiety, generalised), gaze aversion, hand-flapping, self-injurious behaviours. These arise from amygdala hyperreactivity and sensory processing dysfunction	Applied Behaviour Analysis (ABA) for structured skill-building. Cognitive Behavioural Therapy (CBT) adapted for developmental level (for anxiety). Social skills groups. Consistent routines and visual schedules reduce anxiety. Avoid sensory overstimulation in the environment

Why Early Intervention Matters in FXS

The brain has maximal neuroplasticity in the first 3–5 years of life. Although FMRP is absent, the remaining synaptic machinery can be partially compensated by intensive, structured environmental input during this critical window. Children with FXS who receive early intervention show better language outcomes, improved adaptive behaviour, and reduced severity of behavioural difficulties compared to those diagnosed late. This is why the emphasis in senior notes is on making an early diagnosis ^[2].

Intervention	Detail
Parent training and education	Teach parents about FXS, expected developmental trajectory, behavioural management strategies, sensory needs. Reduce parental guilt (especially in carrier mothers). Connect to parent support groups (e.g., National Fragile X Foundation, Hong Kong Society for the Rehabilitation of the Disabled)
Sibling support	Siblings may experience emotional difficulties (worry, jealousy, embarrassment). Age-appropriate information and support groups
Respite care	Caring for a child with moderate-severe ID is exhausting. Arrange respite services to prevent carer burnout
Genetic counselling ^[2]^[3]	Explain inheritance, recurrence risk, implications for maternal relatives (FXPOI, FXTAS risk). Offer prenatal/PGT-M options. See cascade testing below
Transition planning	From adolescence, plan for adult services, vocational training, supported living/employment, guardianship/legal capacity issues

9D. Pharmacological Management (Symptom-Targeted)

There is no FXS-specific approved drug. All medications used are prescribed off-label for specific co-morbid symptoms. The principle is to treat the symptom (ADHD, anxiety, seizures, etc.) using the same medications as in the general paediatric population, with awareness of FXS-specific considerations.

Medication	Class	Mechanism	Dose / Notes in Paediatrics	FXS-Specific Considerations
Methylphenidate	Stimulant	Blocks dopamine and noradrenaline reuptake → increases prefrontal cortex catecholamines → improves attention and impulse control	Start low (e.g., 5 mg immediate-release in AM for school-age child), titrate to effect. Extended-release formulations (e.g., Concerta, Ritalin LA) preferred for school-day coverage	First-line for ADHD in FXS (as in general paediatric ADHD). May cause appetite suppression, insomnia, irritability. Monitor growth (height/weight) at each visit. Some children with FXS tolerate stimulants less well due to comorbid anxiety — if anxiety worsens, consider switching
Dexamphetamine / Lisdexamfetamine	Stimulant	Similar to methylphenidate; releases dopamine + noradrenaline	Second-line stimulant if methylphenidate ineffective or not tolerated	Same considerations as methylphenidate
Atomoxetine	Non-stimulant (selective NRI)	Selectively inhibits noradrenaline reuptake in prefrontal cortex	0.5 mg/kg/day initially, increase over 2–4 weeks to 1.2 mg/kg/day (max ~1.4 mg/kg/day or 100 mg). Takes 4–6 weeks for full effect	Useful when stimulants worsen anxiety (common in FXS). No abuse potential. Less effective for hyperactivity than stimulants but better for anxiety/inattention overlap
Guanfacine extended-release	Alpha-2 adrenergic agonist	Stimulates post-synaptic alpha-2A receptors in prefrontal cortex → enhances attention; also dampens sympathetic overactivity → reduces hyperarousal	1 mg at bedtime, titrate up by 1 mg weekly (max 4 mg/day in children ≥ 6 years)	Particularly useful in FXS because it addresses both ADHD and hyperarousal/anxiety simultaneously. Sedation can be a benefit (helps with sleep disturbance) or a side effect. Monitor BP and HR
Clonidine	Alpha-2 adrenergic agonist	Similar to guanfacine but shorter-acting, less selective	25–50 mcg at bedtime, titrate slowly. Available as transdermal patch	Often used as adjunct to stimulants, or for sleep initiation difficulties. More sedating than guanfacine

ADHD Treatment Hierarchy in FXS

First-line: Methylphenidate (most evidence in FXS)
If anxiety worsens on stimulants: Switch to atomoxetine or guanfacine ER
Adjuncts for hyperarousal/sleep: Guanfacine or clonidine
Combination: Stimulant + alpha-2 agonist if needed

Note: Children with FXS under age 5 may respond less well to stimulants than the general ADHD population. Behavioural strategies should always be the first step, with medication added if insufficient.

Medication	Class	Mechanism	Paediatric Dosing	Notes for FXS
Sertraline	SSRI	Inhibits serotonin reuptake → increases serotonergic tone in limbic circuits → reduces anxiety	Start 12.5–25 mg daily (liquid formulation available for young children), titrate to 50–200 mg/day over weeks	First-line pharmacotherapy for anxiety in FXS. FMRP normally modulates serotonin pathways; SSRIs partially compensate. Also helps with repetitive behaviours/OCD-like symptoms
Fluoxetine	SSRI	Same mechanism	Start 5–10 mg daily, titrate to 20–60 mg/day	Alternative SSRI; longer half-life (advantage if doses missed). Monitor for activation/behavioural disinhibition in young children
Escitalopram	SSRI	Most selective serotonin reuptake inhibitor	Start 5 mg daily, titrate to 10–20 mg/day (approved ≥ 12 years for GAD in many jurisdictions)	Well-tolerated; limited paediatric data under 12

Non-pharmacological approaches for anxiety should always be first-line:

Environmental modification (reduce sensory overload, structured routines, predictable transitions)
Adapted CBT (using visual and concrete strategies appropriate to cognitive level)
Relaxation techniques, deep pressure input

SSRI Precautions in Paediatrics

All SSRIs carry an FDA/MHRA black box warning for increased risk of suicidal ideation in children and adolescents (particularly in the first few weeks of treatment). However, in FXS the cognitive level often means this risk is lower and clinical benefit typically outweighs risk. Close monitoring is still mandatory. Start low, go slow, and monitor frequently.

There is no medication that treats ASD core symptoms (social communication deficits). Management is behavioural:

Applied Behaviour Analysis (ABA)
Social skills training (adapted to cognitive level)
PECS (Picture Exchange Communication System) for non-verbal or minimally verbal children
Structured teaching (TEACCH model)

Medications may be used for associated challenging behaviours (irritability, aggression, self-injury):

Medication	Class	Indication	Paediatric Dosing	Notes
Aripiprazole	Atypical antipsychotic (D2 partial agonist)	Irritability associated with ASD (FDA-approved ≥ 6 years)	Start 2 mg daily, titrate to 5–15 mg/day	Lower risk of metabolic side effects than other atypical antipsychotics. Monitor weight, fasting glucose, lipids, prolactin
Risperidone	Atypical antipsychotic (D2/5-HT2A antagonist)	Irritability associated with ASD (FDA-approved ≥ 5 years)	Start 0.25 mg daily (weight < 20 kg) or 0.5 mg daily (weight ≥ 20 kg), titrate slowly (max ~3 mg/day)	More weight gain and prolactin elevation than aripiprazole. Monitor regularly

Seizures in FXS typically present in childhood and often remit by adolescence ^[1]. They are usually focal or generalised tonic-clonic, and often respond well to standard anticonvulsants.

Medication	Indication	Notes for FXS
Sodium valproate (VPA)	Broad-spectrum AED; useful for generalised seizures	Effective in FXS-related seizures. Caution: weight gain (additive with atypical antipsychotics), teratogenicity (critical counselling for adolescent females — avoid in females of child-bearing potential if possible)
Levetiracetam	Broad-spectrum AED	Often preferred in FXS due to favourable side-effect profile and no drug interactions. Can rarely cause behavioural side effects (irritability) — monitor closely in a population already prone to behavioural challenges
Carbamazepine / Oxcarbazepine	Focal seizures	Effective for focal seizures. Carbamazepine may interact with other medications (CYP3A4 inducer). Oxcarbazepine has fewer interactions
Lamotrigine	Broad-spectrum	Good option; may have mood-stabilising benefits. Requires slow titration to avoid Stevens-Johnson syndrome (especially if used with VPA, which inhibits lamotrigine metabolism)

Key principle: Seizures in FXS are usually benign and self-limiting. Many children can be weaned off AEDs in adolescence after a seizure-free period of 2+ years. Standard paediatric epilepsy management guidelines apply.

Approach	Detail
Sleep hygiene (first-line)	Consistent bedtime routine, dark quiet room, avoid screens before bed, weighted blanket (sensory benefit), reduce caffeine
Melatonin	0.5–5 mg at bedtime (start low). FMRP is involved in circadian gene regulation; melatonin production may be dysregulated. Well-tolerated with minimal side effects. Available as liquid or tablets. Often very effective in FXS
Clonidine	25–50 mcg at bedtime. Useful for sleep-onset difficulty and can also address hyperarousal/ADHD (dual benefit)

Target Symptom	First-Line Drug	Second-Line / Adjunct	Key Monitoring
ADHD	Methylphenidate	Atomoxetine, guanfacine ER	Growth (height/weight), BP, HR, appetite, sleep
Anxiety	SSRI (sertraline)	Fluoxetine, escitalopram; non-pharm first	Suicidal ideation (black box), activation, GI upset
Irritability / Aggression	Aripiprazole	Risperidone	Weight, fasting glucose/lipids, prolactin
Seizures	Levetiracetam or VPA	Lamotrigine, carbamazepine	Seizure diary; VPA: LFTs, weight, teratogenicity
Sleep	Melatonin	Clonidine	Sedation, BP (clonidine)

Age / Stage	Surveillance Action	Rationale
At diagnosis	Baseline developmental assessment, echo, ophthalmology, audiology, orthopaedic exam	Establish baseline; detect existing complications
Annually (childhood)	Developmental/adaptive reassessment, growth parameters, behavioural screen (ADHD, anxiety, ASD), seizure history, orthopaedic check (scoliosis, flat feet)	Track progress; adjust therapies; detect new issues
Puberty	Testicular volume (Prader orchidometer), repeat echo for MVP, review AED need if seizures have remitted, anticipate behavioural changes	Macro-orchidism develops post-puberty ^[1]^[2]; MVP may become apparent; seizures often remit
Adolescence / Transition	Transition planning to adult services, vocational assessment, legal capacity/guardianship, reproductive counselling (for female carriers), review all medications	Prepare for adult life; many paediatric services end at 18

Genetic counselling for the maternal family is essential ^[2]^[3]. This is a non-negotiable part of management.

Action	Detail
Test the mother	Determine her CGG repeat number and carrier status
Test siblings	May be affected (particularly brothers) or carriers (sisters)
Test maternal aunts, grandmother, female cousins ^[3]	They may carry the premutation or full mutation → at risk for: having FXS children, FXPOI, or FXTAS
Reproductive counselling	For known carriers: options include CVS, amniocentesis, PGT-M, donor egg/sperm, adoption
FXPOI counselling	Female premutation carriers (~20% risk of premature ovarian failure before age 40): consider early fertility assessment and family planning
FXTAS counselling	Male premutation carriers (and occasionally females) > 50 years: risk of progressive tremor/ataxia syndrome

While not yet standard of care, several targeted therapies based on the "mGluR theory of Fragile X" have been investigated. Understanding these demonstrates the translational potential of FXS pathophysiology research:

Agent	Mechanism	Status
mGluR5 antagonists (mavoglurant, basimglurant)	Block excessive mGluR5 signalling (normally inhibited by FMRP) → reduce exaggerated LTD → restore synaptic balance	Phase II/III trials showed no significant benefit on primary endpoints in FXS; development halted
GABA-B agonists (arbaclofen)	Enhance inhibitory GABAergic tone to counteract excitation-inhibition imbalance	Mixed results in clinical trials; some improvement in social avoidance subscale but primary endpoints not met
Cannabidiol (CBD)	Multiple mechanisms including modulation of endocannabinoid system, anti-anxiety	Anecdotal reports of behavioural improvement; ongoing trials
FMR1 gene reactivation (CRISPR-based demethylation, small molecules like 5-azacytidine)	Remove methylation from FMR1 promoter → re-express FMRP	Preclinical/experimental only; potential toxicity concerns with demethylating agents
Metformin	Normalises ERK and mTOR signalling pathways (downstream of mGluR5)	Open-label studies showed improvements in behaviour and language in some children with FXS; randomised controlled trials ongoing

Why Did mGluR5 Antagonists Fail?

The "mGluR theory" was elegant — FMRP normally brakes mGluR5-driven protein synthesis; without FMRP, there is excessive mGluR5 signalling → blocking mGluR5 should restore balance. This worked beautifully in animal models (Fmr1 knockout mice). However, human trials failed, likely because: (1) chronic mGluR5 blockade may have compensatory effects, (2) outcome measures in trials were insensitive, (3) the human FXS phenotype involves more than just mGluR5 dysregulation, and (4) treatment may need to start much earlier (in infancy) before irreversible synaptic damage occurs. This remains an active area of research.

Medication	Contraindication / Caution	Why
Stimulants (methylphenidate)	Relative caution if severe anxiety or tics	Stimulants can exacerbate anxiety (common in FXS) and tics. If this occurs, switch to non-stimulant (atomoxetine or guanfacine)
SSRIs	Caution in children < 6 years (limited evidence); monitor for activation/disinhibition	Younger children with developmental delay may be unable to articulate suicidal ideation → rely on behavioural monitoring
Valproate	Avoid in adolescent females of childbearing potential if possible	Teratogenicity (neural tube defects, developmental delay in offspring); use levetiracetam or lamotrigine instead
Risperidone / Aripiprazole	Monitor metabolic parameters; caution with prolonged use	Weight gain → obesity (already a risk in FXS due to reduced physical activity); metabolic syndrome; prolactin elevation (risperidone > aripiprazole)
Clonidine	Avoid abrupt withdrawal	Rebound hypertension; taper gradually
Carbamazepine	Drug interactions (potent CYP inducer)	Can reduce levels of co-administered medications; check for HLA-B*1502 in Han Chinese population (risk of SJS/TEN)

High Yield Summary – Management of FXS

No cure exists; management is supportive, symptomatic, and multidisciplinary
Early diagnosis → early intervention is the single most important step ^[2]
Core therapies: speech-language therapy, OT, physiotherapy, special education (IEP) ^[2]
Pharmacotherapy is symptom-targeted (not FXS-specific):
- ADHD → methylphenidate first-line; guanfacine if anxiety co-exists
- Anxiety → SSRI (sertraline); behavioural/environmental strategies first
- Irritability/aggression → aripiprazole or risperidone
- Seizures → levetiracetam or valproate; often remit by adolescence
- Sleep → melatonin; clonidine as adjunct
Genetic counselling and cascade testing of maternal relatives is mandatory ^[2]^[3]
Medical surveillance: echo for MVP, ophthalmology, audiology, scoliosis screening, pubertal monitoring for macro-orchidism
Transition planning for adolescents to adult services is essential
mGluR5 antagonists failed in clinical trials despite strong preclinical rationale; metformin is under investigation

Active Recall - Management of Fragile X Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 882–883) ^[3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26)

Complications of Fragile X Syndrome

The complications of FXS stem directly from the absence of FMRP and its downstream effects on multiple organ systems. FMRP is not just a "brain protein" — it is expressed broadly, including in neurons, connective tissue, cardiac valves, testes, and the retina. Therefore, complications span neurodevelopmental, behavioural/psychiatric, cardiac, musculoskeletal, and reproductive domains.

It is also important to distinguish between:

Complications intrinsic to FXS (direct consequences of absent FMRP)
Complications of the premutation state (RNA toxicity — a different mechanism, affecting different individuals)
Iatrogenic complications (side effects of medications used to manage FXS symptoms)

10B. Neurodevelopmental and Cognitive Complications

Feature	Detail	Pathophysiological Basis
Moderate-to-severe ID in males (IQ 20–80, mean ~50) ^[1]^[9]	The defining complication of FXS. Affects learning, adaptive function, independence, vocational capacity, and quality of life	Absent FMRP → unregulated synaptic protein synthesis → immature dendritic spines → impaired synaptic plasticity and learning circuits
Mild-to-moderate ID in ~40–50% of females with full mutation ^[1]	Variable due to X-inactivation; some females have normal IQ but still have executive function difficulties	Random lyonisation: favourable X-inactivation ratio → more normal X active → more FMRP → milder phenotype
Cognitive decline (apparent, not true regression)	Cognitive level and adaptive behaviour skills decline after early childhood, reflecting the slow acquisition of skills compared with other children of the same age rather than a regression of skills ^[2]	Skills are acquired more slowly than peers → widening gap over time → apparent "decline" in standardised scores. This is NOT neurodegeneration

Important Distinction – Apparent Decline vs. True Regression

Parents and clinicians may perceive a "decline" in IQ scores over childhood. This is an artefact of standardised testing: as the child ages, peers acquire skills faster, so the FXS child's relative score drops even though they are still learning new things. True regression (loss of previously acquired skills) does NOT occur in FXS ^[2]. If genuine regression occurs, investigate for another diagnosis (Rett syndrome, metabolic disorder, epileptic encephalopathy).

Complication	Detail	Mechanism
Delayed language development	Expressive language skills achieved more slowly than receptive language skills ^[2]	FMRP regulates mRNA for synaptic proteins in Broca's area (expressive language) and broader language networks; expressive circuits may be more vulnerable
Characteristic speech cluttering	Rapid, irregular rate makes speech difficult to understand ^[2]	Motor speech planning dysfunction + executive function impairment (difficulty regulating speech output rate)
Perseverative / repetitive speech	Echolalia, repetitive phrases, tangential conversation	Frontal lobe executive dysfunction → inability to inhibit verbal output

Feature	Detail
Prevalence in FXS	~30% of males with FXS meet DSM-5 criteria for ASD; ~20% meet broader ASD criteria without full diagnosis ^[5]^[6]^[14]
Features	Social anxiety with gaze aversion (but often socially interested — distinct from "classic" ASD), hand flapping, stereotypic movements, sensory hypersensitivity, difficulty with social reciprocity
Impact	ASD co-morbidity is associated with lower cognitive outcomes, more challenging behaviours, and greater need for intensive support

GC Lecture Slide – High Yield

GC 151 ^[14] lists Fragile X syndrome as one of several rare diseases found among common diseases — specifically naming FXS alongside isodicentric chromosome 15, distal 16p11.2 deletion, PTEN mutation, and Phelan-McDermid syndrome (SHANK3/22q13 deletion) as genetic causes identified within ASD cohorts. This reinforces that FXS should always be considered in the genetic workup of ASD ^[14].

Feature	Detail
Prevalence	~80% of males with FXS have clinically significant ADHD symptoms
Subtype	Combined type (inattention + hyperactivity-impulsivity) most common
Complication	ADHD significantly impairs educational attainment and social functioning beyond what ID alone causes; adds to behavioural management challenges

Complication	Prevalence	Mechanism	Impact
Anxiety disorders (social anxiety, generalised anxiety, selective mutism)	~70–80% of males	Amygdala hyperreactivity due to absent FMRP modulation of fear circuits; sensory overload → hyperarousal	Social avoidance, school refusal, difficulty in group settings, self-injurious behaviour when overwhelmed
Sensory hypersensitivity (hyperacusis, tactile defensiveness)	Very common	Excessive mGluR5-driven excitatory signalling → lowered sensory threshold	Environmental adaptations required; contributes to meltdowns and avoidance behaviours
Aggression / Self-injurious behaviour (SIB)	~30–50%	Frustration from communication difficulty + sensory overload + anxiety → behavioural dysregulation	Hand-biting (characteristic), head-banging, hitting. May require behavioural intervention ± pharmacotherapy
Mood disorders	Less well-characterised in children; depression can emerge in adolescence	Serotonergic dysfunction (FMRP modulates serotonin receptor mRNA)	Screen for depression in adolescents, especially those with insight into their differences
Sleep disturbance	~30–50%	Dysregulated melatonin production (FMRP involved in circadian gene expression)	Impacts daytime behaviour, learning, family functioning; often responds to melatonin

Complication	Prevalence	Mechanism	Clinical Significance
Mitral valve prolapse (MVP) ^[1]^[2]	~50% of adults with FXS; less common in childhood	FMRP regulates extracellular matrix proteins (elastin, collagen) → connective tissue dysplasia → myxomatous degeneration of mitral valve leaflets (similar to Marfan syndrome)	Usually benign — mid-systolic click ± late systolic murmur on auscultation. Majority have no significant mitral regurgitation (MR). Echo surveillance recommended. If significant MR develops → volume overload → LV dilatation → heart failure (rare in paediatric FXS)
Mitral regurgitation (MR)	Subset of those with MVP	MVP → leaflet malcoaptation → regurgitant jet during systole	If moderate-severe MR: endocarditis prophylaxis in specific dental/surgical procedures (per current guidelines); cardiology follow-up. Surgical intervention (valve repair/replacement) is exceedingly rare in FXS
Aortic root dilatation	Rare	Connective tissue dysplasia affecting aortic wall (similar mechanism to MVP)	Much less common than in Marfan syndrome. Echo screening at baseline; repeat if abnormal

MVP in FXS – Usually Benign But Requires Monitoring

Unlike Marfan syndrome where aortic complications are life-threatening, the cardiac complications of FXS are generally mild and well-tolerated. Most children with FXS and MVP are asymptomatic. However, baseline echocardiography at diagnosis is recommended, with repeat in adolescence/adulthood, to detect the minority who develop significant MR ^[1]^[2].

Complication	Prevalence	Mechanism	Management
Joint hypermobility ^[1]^[2]	Very common (> 50%)	FMRP regulates elastin/collagen gene expression → reduced structural integrity of ligaments and joint capsules	May cause joint instability, recurrent subluxations (especially fingers, patella), pain during physical activity. Physiotherapy for joint strengthening; avoid high-impact sports that stress hypermobile joints
Pes planus (flat feet)	Very common	Ligamentous laxity of foot arches	Custom orthotics/arch supports; supportive footwear; physiotherapy for intrinsic foot muscles
Scoliosis ^[1]	~20% of affected individuals	Hypotonia + connective tissue laxity → vertebral malalignment; may worsen during growth spurts	Regular spinal screening (Adams forward bend test) at each visit; referral to orthopaedics if curve > 10°; bracing for moderate curves; surgery rarely needed
Recurrent otitis media	Common in childhood	Eustachian tube dysfunction (likely related to connective tissue laxity of tubal cartilage + hypotonia of tensor veli palatini) → poor middle ear ventilation → recurrent infection	May cause conductive hearing loss if chronic → impacts language development (already vulnerable). Aggressive management: antibiotics, grommets (tympanostomy tubes) if recurrent. Audiology screening at diagnosis and regularly

Feature	Detail
Prevalence	~10–20% of males with FXS ^[1]
Seizure types	Most commonly benign focal seizures (especially centrotemporal, resembling benign epilepsy with centrotemporal spikes / BECTS) or generalised tonic-clonic seizures
Age of onset	Typically childhood (2–10 years)
Prognosis	Usually remit by adolescence — many children can be weaned off anticonvulsants after a seizure-free period
Complications of seizures	Injury during seizures, cognitive impact if uncontrolled (status epilepticus is rare), drug side effects, impact on school attendance
EEG findings	May show centrotemporal spikes (similar to BECTS) or generalised spike-wave discharges

Complication	Prevalence	Mechanism	Management
Strabismus ^[2]	Common (~30–40%)	Impaired coordination of extraocular muscles (related to neurological dysfunction + possible connective tissue factors)	Ophthalmology referral; patching therapy, corrective lenses, or surgical correction if persistent
Refractive errors (hypermetropia, myopia, astigmatism)	Common	Altered eye growth and lens development	Regular refraction checks; corrective lenses
Nystagmus	Occasional	Central nervous system involvement	Evaluate for underlying cause

Complication	Who Is Affected	Mechanism	Notes
Macro-orchidism ^[1]^[2]	Post-pubertal males with full mutation (> 80%)	Absent FMRP → unregulated Sertoli cell proliferation → seminiferous tubule enlargement (NOT due to increased testosterone; testicular function is usually normal)	Testicular volume > 25–30 mL (normal adult 15–25 mL). Fertility is usually preserved in males with FXS (unlike Klinefelter syndrome). The concern is cosmetic/psychosocial rather than functional
Fragile X-associated Primary Ovarian Insufficiency (FXPOI)	Female premutation carriers (~20%)	RNA toxicity from excess FMR1 mRNA (premutation mechanism, NOT full mutation) → damages ovarian follicles → accelerated follicular depletion	Menopause before age 40. NOT a complication of FXS per se but of the premutation. Important for genetic counselling of carrier mothers/aunts — early fertility assessment is recommended
FXTAS	Male (and occasionally female) premutation carriers > 50 years	RNA gain-of-function toxicity → intranuclear inclusions in neurons/astrocytes → progressive cerebellar ataxia, intention tremor, cognitive decline, parkinsonism	NOT a complication of FXS (full mutation) but of the premutation state. Important to counsel families that premutation grandfathers/uncles may develop this progressive neurodegenerative condition

FXPOI and FXTAS Are Premutation Complications, NOT Full-Mutation Complications

A common exam error is attributing FXPOI and FXTAS to FXS (full mutation). These conditions are caused by the premutation (55–200 repeats) through RNA toxicity (excess FMR1 mRNA), which is a completely different mechanism from the full mutation (gene silencing → absent FMRP). Individuals with the full mutation do NOT develop FXTAS or FXPOI. However, their carrier mothers/maternal relatives (premutation carriers) may be at risk — which is why cascade testing and counselling is essential ^[1]^[2]^[3].

Complication	Detail
Impact on the child	Social isolation (due to anxiety, behavioural challenges, ID), bullying at school, reduced self-esteem (especially in those with mild-moderate ID who have some insight), difficulty forming friendships, limited vocational opportunities in adulthood
Impact on parents	Maternal guilt (carrier mothers often feel responsible), chronic stress from caring for a child with moderate-severe ID + behavioural challenges, financial burden (therapies, special education), marital strain, anxiety about recurrence risk in future pregnancies
Impact on siblings	Emotional burden ("parentification" of older siblings), worry about their own carrier status, less parental attention, adjustment difficulties
Impact on maternal relatives	Learning of premutation carrier status may cause anxiety about own health (FXPOI risk, FXTAS risk) and reproductive implications

Treatment	Potential Complication	Monitoring
Methylphenidate (for ADHD)	Appetite suppression → weight loss/growth deceleration; insomnia; exacerbation of anxiety; tics; rebound irritability	Height/weight at each visit; sleep diary; anxiety screening
SSRIs (for anxiety)	Activation/behavioural disinhibition (especially in young children); GI upset; serotonin syndrome (rare, if combined with other serotonergic agents)	Behavioural monitoring in first 4–6 weeks; suicidal ideation monitoring in adolescents
Atypical antipsychotics (aripiprazole, risperidone)	Weight gain → metabolic syndrome (obesity, dyslipidaemia, insulin resistance, T2DM); prolactin elevation (risperidone > aripiprazole) → gynaecomastia, galactorrhoea; sedation; extrapyramidal symptoms (rare with atypicals)	Fasting glucose/lipids, weight, BMI, prolactin, waist circumference every 6–12 months
Valproate (for seizures)	Teratogenicity (neural tube defects, neurodevelopmental harm in offspring) if used in females of childbearing potential; weight gain; hepatotoxicity (rare, more common < 2 years); thrombocytopenia; pancreatitis (rare)	LFTs, CBP, weight; contraception counselling in adolescent females; consider alternative AED
Melatonin (for sleep)	Generally very safe; occasionally daytime drowsiness, vivid dreams, headache	Rarely requires monitoring; assess effectiveness regularly

Aspect	Outcome
Life expectancy	Normal or near-normal in FXS. Unlike some genetic syndromes (e.g., Down syndrome with major cardiac defects, or storage disorders), FXS does not typically shorten lifespan significantly
Independence	Males with moderate-severe ID usually require supported living in adulthood (supervised group homes, day programmes). Some with mild-moderate ID can achieve semi-independent living with support
Employment	Most males with FXS require sheltered or supported employment. Females with mild ID may achieve competitive employment with accommodations
Relationships	Social anxiety can limit social networks. Some individuals with FXS form meaningful friendships and romantic relationships, particularly those with milder phenotypes
Fertility	Males with FXS are usually fertile (macro-orchidism does not impair spermatogenesis). If a male with the full mutation reproduces (rare due to severity of ID), all daughters will be obligate premutation carriers (the full mutation contracts back to premutation during spermatogenesis)

System	Complication	Prevalence	Severity
Neurodevelopmental	ID (moderate-severe in males)	~100% of males with full mutation	Core feature; lifelong
Behavioural/Psychiatric	ADHD, anxiety, ASD, aggression, sleep disturbance	70–80% (ADHD/anxiety); ~30% (ASD)	Variable; manageable with multimodal approach
Seizures	Focal/generalised seizures	10–20%	Usually benign; often remit by adolescence
Cardiovascular	MVP ± MR	~50% of adults	Usually mild and asymptomatic
Musculoskeletal	Joint laxity, scoliosis, flat feet	> 50%	Functional impairment possible; rarely severe
Ophthalmological	Strabismus, refractive errors	30–40%	Treatable
ENT	Recurrent otitis media, conductive hearing loss	Common in childhood	Can worsen language delay if untreated
Genital	Macro-orchidism	> 80% post-pubertal males	Cosmetic concern; fertility usually preserved
Premutation-specific	FXPOI, FXTAS	20% (FXPOI); variable (FXTAS)	Affects premutation carriers, NOT full mutation

High Yield Summary – Complications of FXS

ID is the core complication — moderate-severe in males (IQ 20–80, mean ~50), mild-moderate in ~40–50% of females ^[1]
Apparent cognitive "decline" is due to slowing of skill acquisition relative to peers, NOT true regression ^[2]
ADHD (~80%), anxiety (~70–80%), and ASD (~30%) are the most impactful behavioural co-morbidities
Seizures (10–20%) are usually benign and remit by adolescence ^[1]
MVP (~50% of adults) is usually asymptomatic; echo surveillance recommended ^[1]^[2]
Joint laxity, scoliosis, flat feet — connective tissue complications requiring physiotherapy and monitoring
Macro-orchidism develops post-puberty; fertility is usually preserved
Strabismus and recurrent otitis media should be screened for at diagnosis to prevent worsening of language delay
FXPOI and FXTAS are premutation complications (RNA toxicity), NOT full-mutation complications — important distinction for counselling
Life expectancy is normal — the main impact is on quality of life, independence, and psychosocial functioning
Iatrogenic complications from ADHD medications, antipsychotics, and AEDs require regular monitoring

Active Recall - Complications of Fragile X Syndrome

References

^[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 497) ^[2] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (pp. 880, 882–883) ^[3] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 26) ^[5] Senior notes: Adrian Lui Pediatrics Notes.pdf (p. 86) ^[6] Senior notes: Ryan Ho Psychiatry.pdf (pp. 244, 251, 256) ^[9] Senior notes: Maksim Paediatric Notes.pdf (p. 207) ^[14] GC Lecture slides: GC 151. The malformed child hereditary syndromes and anomalies.pdf (p. 24)

High Yield Summary

Fragile X Syndrome – Key Points for Exams:

Most common inherited cause of intellectual disability (distinguish from Down syndrome, which is the most common genetic cause overall)
X-linked; FMR1 gene at Xq27.3; CGG trinucleotide repeat expansion in the 5' UTR (non-coding region)
99% caused by trinucleotide repeat expansion → hypermethylation → absent FMRP
Repeat ranges: Normal (~5–44), Premutation (55–200), Full mutation ( > 200)
Full mutation: gene silenced → no FMRP → loss of function
Premutation: gene overactive → excess mRNA → RNA toxicity (FXTAS, FXPOI)
Anticipation: repeats expand through generations (especially maternal transmission)
Sherman Paradox: unaffected male → carrier daughter → affected grandson
Clinical triad: Intellectual disability + Large ears/long face + Macro-orchidism (after puberty)
Associated features: ASD (~30%), ADHD, anxiety, joint laxity, MVP, seizures (10–20%)
Females: 40–50% with full mutation have learning difficulty (variable due to X-inactivation)
Diagnosis: Molecular analysis of CGG repeat number in FMR1 (NOT standard karyotype)
Standard karyotype is NORMAL (46,XY) – fragile site only seen under special conditions
Genetic counselling of maternal relatives is mandatory

High Yield Summary – Diagnosis of FXS

FXS is diagnosed by molecular testing (FMR1 CGG repeat analysis), NOT by karyotype or CMA ^[3]
Karyotype is NORMAL in FXS (46,XY or 46,XX) ^[3]
Two-step molecular approach: PCR (screening) → Southern blot (confirmation of full mutation + methylation)
Full mutation = > 200 CGG repeats + hypermethylation → FMR1 silenced → absent FMRP
Premutation = 55–200 repeats → gene ACTIVE → RNA toxicity (not classic FXS but risk of FXTAS/FXPOI)
Test any child with unexplained GDD, ID, or ASD for FXS
Cascade testing of maternal relatives is mandatory after diagnosis
Post-diagnosis: developmental assessment, echo for MVP, ophthalmology, audiology, seizure monitoring

High Yield Summary – Management of FXS

No cure exists; management is supportive, symptomatic, and multidisciplinary
Early diagnosis → early intervention is the single most important step ^[2]
Core therapies: speech-language therapy, OT, physiotherapy, special education (IEP) ^[2]
Pharmacotherapy is symptom-targeted (not FXS-specific):
- ADHD → methylphenidate first-line; guanfacine if anxiety co-exists
- Anxiety → SSRI (sertraline); behavioural/environmental strategies first
- Irritability/aggression → aripiprazole or risperidone
- Seizures → levetiracetam or valproate; often remit by adolescence
- Sleep → melatonin; clonidine as adjunct
Genetic counselling and cascade testing of maternal relatives is mandatory ^[2]^[3]
Medical surveillance: echo for MVP, ophthalmology, audiology, scoliosis screening, pubertal monitoring for macro-orchidism
Transition planning for adolescents to adult services is essential
mGluR5 antagonists failed in clinical trials despite strong preclinical rationale; metformin is under investigation

High Yield Summary – Complications of FXS

ID is the core complication — moderate-severe in males (IQ 20–80, mean ~50), mild-moderate in ~40–50% of females ^[1]
Apparent cognitive "decline" is due to slowing of skill acquisition relative to peers, NOT true regression ^[2]
ADHD (~80%), anxiety (~70–80%), and ASD (~30%) are the most impactful behavioural co-morbidities
Seizures (10–20%) are usually benign and remit by adolescence ^[1]
MVP (~50% of adults) is usually asymptomatic; echo surveillance recommended ^[1]^[2]
Joint laxity, scoliosis, flat feet — connective tissue complications requiring physiotherapy and monitoring
Macro-orchidism develops post-puberty; fertility is usually preserved
Strabismus and recurrent otitis media should be screened for at diagnosis to prevent worsening of language delay
FXPOI and FXTAS are premutation complications (RNA toxicity), NOT full-mutation complications — important distinction for counselling
Life expectancy is normal — the main impact is on quality of life, independence, and psychosocial functioning
Iatrogenic complications from ADHD medications, antipsychotics, and AEDs require regular monitoring

Fragile X Syndrome

1. Definition

2. Epidemiology

Incidence and Prevalence

Key Epidemiological Points

3. Anatomy and Function of FMR1/FMRP

The FMR1 Gene

FMRP – What Does It Do?

4. Aetiology and Pathophysiology

4A. The Trinucleotide Repeat Expansion Mechanism

4B. Categories of CGG Repeat Length

4C. Step-by-Step Pathophysiology of Full Mutation

4D. Premutation: A Distinct Pathophysiology

4E. Inheritance Pattern and the "Sherman Paradox"

4F. Why Is X-Inactivation Important in Females?

5. Classification

5A. By Mutation Size

5B. By Phenotypic Severity in Males with Full Mutation

5C. Related Fragile X Conditions (The "Fragile X Spectrum")

6. Clinical Features

6A. Symptoms (What the parents/child report)

6B. Signs (What the clinician observes on examination)

Craniofacial Features

Musculoskeletal / Connective Tissue Features

Genital Findings

Cardiovascular Findings

Neurological and Behavioural Signs

6C. Age-Dependent Clinical Presentation

6D. Clinical Features in Females with Full Mutation

6E. Summary Table of Clinical Features (High Yield)

7. Family-Centred Care and Communication Considerations

Communicating with the Family

Consent and Assent

Active Recall - Fragile X Syndrome

References

Thinking Framework: Why Is Differential Diagnosis Important in FXS?

7A. Approach to the Differential Diagnosis

7B. Differential Diagnosis Table — Organised by Clinical Overlap

I. Genetic Syndromes Presenting with ID ± Dysmorphism (Primary DDx)

II. Conditions with Connective Tissue Overlap

III. Conditions with ASD / Behavioural Overlap

IV. Conditions with Seizures + ID Overlap

V. Other Causes of GDD/ID to Consider (Non-Syndromic)

7C. Approach to Differentiating FXS from Key Mimics — Clinical Decision Points

7D. When Should You Specifically Test for FXS?

7E. Summary: Top 5 Differential Diagnoses to Consider for FXS

Active Recall - Differential Diagnosis of Fragile X Syndrome

8A. Why Standard "Diagnostic Criteria" Differ from Other Conditions

8B. Indications for Molecular Testing — Who Should Be Tested?

In Children (Paediatric Focus)

In Adults

8C. Diagnostic Algorithm

8D. Investigation Modalities, Key Findings, and Interpretation

I. Primary Diagnostic Test: FMR1 Molecular Analysis

a) PCR-Based CGG Repeat Sizing

b) Southern Blot Analysis

c) Combined Approach (Standard of Care)

Interpretation Summary Table

II. Investigations That Do NOT Diagnose FXS (But Are Often Done First)

III. Supportive / Post-Diagnosis Investigations

IV. Cascade Genetic Testing of Family Members

V. Prenatal and Preimplantation Diagnosis

8E. Historical Diagnostic Method (For Completeness)

8F. Summary of Diagnostic Approach

Active Recall - Diagnosis of Fragile X Syndrome

9A. Overarching Management Philosophy

9B. Management Algorithm

9C. Non-Pharmacological Management (Cornerstone of Treatment)

I. Early Intervention Programme

II. Family-Centred Care and Psychosocial Support

9D. Pharmacological Management (Symptom-Targeted)

I. ADHD Symptoms (~80% of males with FXS)

II. Anxiety (~70–80% of males with FXS)

III. ASD Features (~30% of males with FXS)

IV. Seizures (~10–20% of males with FXS)

V. Sleep Disturbances (~30–50%)

VI. Summary Table of Pharmacological Management

9E. Medical Surveillance and Monitoring

9F. Genetic Counselling and Cascade Testing (Mandatory Component)

9G. Emerging / Investigational Therapies